The Impact of Switching to a Second Antifibrotic in Patients
With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre
Study From the EMPIRE Registry

J 2024

The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry

GREGOR, Jakub, Yochai ADIR, Martina STERCLOVA, Nesrin MOGULKOC, Mordechai R KRAMER et. al.

Basic information

Original name

The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry

Authors

GREGOR, Jakub (203 Czech Republic, belonging to the institution), Yochai ADIR, Martina STERCLOVA (203 Czech Republic), Nesrin MOGULKOC, Mordechai R KRAMER, Martina DOUBKOVÁ (203 Czech Republic, belonging to the institution), Martina PLACKOVA (203 Czech Republic), Veronika MULLER, Michael STUDNICKA (203 Czech Republic), Monika ZURKOVA (203 Czech Republic), Ladislav LACINA (203 Czech Republic), Katarzyna LEWANDOWSKA, Vladimir BARTOS (203 Czech Republic), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution) and Martina KOZIAR VASAKOVA (203 Czech Republic)

Edition

ARCHIVOS DE BRONCONEUMOLOGIA, BARCELONA, ELSEVIER ESPANA SLU, 2024, 0300-2896

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30203 Respiratory systems

Country of publisher

Spain

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 8.000 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.arbres.2023.12.002

UT WoS

001170483700001

Keywords in English

Registries; Antifibrotic agents; Survival; Treatment switch

Abstract

V originále

Introduction: Most patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotics (AF) have progressive disease despite treatment. A switch of AF may improve survival, but evidence from randomised controlled trials is missing. We aimed to evaluate the efficacy of an AF switch on survival and FVC decline in patients from the European MultiPartner IPF registry (EMPIRE). Methods: The study included 612 patients who discontinued the first antifibrotic therapy. Patients were grouped and analysed from two perspectives: (1) whether they had received a second antifibrotic treatment after the discontinuation of the first therapy, and (2) a reason for discontinuation of the first AF - "lack of efficacy" (LE) and "intolerance" (INT). Results: While 263 (43%) of 612 patients received no second AF ("non-switched"), 349 (57%) patients switched. Overall survival was higher in patients who received a second AF (median 50 vs. 29 months; adjusted HR 0.64, P=0.023). Similarly, the annual FVC decline was significantly reduced in switched patients: -98ml/y in switched and -172ml/y in non-switched patients (P=0.023), respectively. The switched patients had similar risk for mortality in both LE and INT groups (adjusted HR 0.95, P=0.85). The high impact of switching on survival was demonstrated in LE patients (adjusted HR 0.27, P<0.001). Conclusion: The patients without a second AF had significantly shorter overall survival. Our analysis suggests the importance of switching patients with an ineffective first AF therapy to a second AF therapy.

Citovat

GREGOR, Jakub, Yochai ADIR, Martina STERCLOVA, Nesrin MOGULKOC, Mordechai R KRAMER, Martina DOUBKOVÁ, Martina PLACKOVA, Veronika MULLER, Michael STUDNICKA, Monika ZURKOVA, Ladislav LACINA, Katarzyna LEWANDOWSKA, Vladimir BARTOS, Petra OVESNÁ, Ondřej MÁJEK and Martina KOZIAR VASAKOVA. The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry. ARCHIVOS DE BRONCONEUMOLOGIA. BARCELONA: ELSEVIER ESPANA SLU, 2024, vol. 60, No 2, p. 80-87. ISSN 0300-2896. Available from: https://dx.doi.org/10.1016/j.arbres.2023.12.002.

@article{2398860,
   author = {Gregor, Jakub and Adir, Yochai and Sterclova, Martina and Mogulkoc, Nesrin and Kramer, Mordechai R and Doubková, Martina and Plackova, Martina and Muller, Veronika and Studnicka, Michael and Zurkova, Monika and Lacina, Ladislav and Lewandowska, Katarzyna and Bartos, Vladimir and Ovesná, Petra and Májek, Ondřej and Koziar Vasakova, Martina},
   article_location = {BARCELONA},
   article_number = {2},
   doi = {http://dx.doi.org/10.1016/j.arbres.2023.12.002},
   keywords = {Registries; Antifibrotic agents; Survival; Treatment switch},
   language = {eng},
   issn = {0300-2896},
   journal = {ARCHIVOS DE BRONCONEUMOLOGIA},
   title = {The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry},
   url = {https://www.sciencedirect.com/science/article/pii/S0300289623004039?via%3Dihub},
   volume = {60},
   year = {2024}
}

TY  - JOUR
ID  - 2398860
AU  - Gregor, Jakub - Adir, Yochai - Sterclova, Martina - Mogulkoc, Nesrin - Kramer, Mordechai R - Doubková, Martina - Plackova, Martina - Muller, Veronika - Studnicka, Michael - Zurkova, Monika - Lacina, Ladislav - Lewandowska, Katarzyna - Bartos, Vladimir - Ovesná, Petra - Májek, Ondřej - Koziar Vasakova, Martina
PY  - 2024
TI  - The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry
JF  - ARCHIVOS DE BRONCONEUMOLOGIA
VL  - 60
IS  - 2
SP  - 80-87
EP  - 80-87
PB  - ELSEVIER ESPANA SLU
SN  - 03002896
KW  - Registries
KW  - Antifibrotic agents
KW  - Survival
KW  - Treatment switch
UR  - https://www.sciencedirect.com/science/article/pii/S0300289623004039?via%3Dihub
N2  - Introduction: Most patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotics (AF) have progressive disease despite treatment. A switch of AF may improve survival, but evidence from randomised controlled trials is missing. We aimed to evaluate the efficacy of an AF switch on survival and FVC decline in patients from the European MultiPartner IPF registry (EMPIRE). Methods: The study included 612 patients who discontinued the first antifibrotic therapy. Patients were grouped and analysed from two perspectives: (1) whether they had received a second antifibrotic treatment after the discontinuation of the first therapy, and (2) a reason for discontinuation of the first AF - "lack of efficacy" (LE) and "intolerance" (INT). Results: While 263 (43%) of 612 patients received no second AF ("non-switched"), 349 (57%) patients switched. Overall survival was higher in patients who received a second AF (median 50 vs. 29 months; adjusted HR 0.64, P=0.023). Similarly, the annual FVC decline was significantly reduced in switched patients: -98ml/y in switched and -172ml/y in non-switched patients (P=0.023), respectively. The switched patients had similar risk for mortality in both LE and INT groups (adjusted HR 0.95, P=0.85). The high impact of switching on survival was demonstrated in LE patients (adjusted HR 0.27, P<0.001). Conclusion: The patients without a second AF had significantly shorter overall survival. Our analysis suggests the importance of switching patients with an ineffective first AF therapy to a second AF therapy.
ER  -

GREGOR, Jakub, Yochai ADIR, Martina STERCLOVA, Nesrin MOGULKOC, Mordechai R KRAMER, Martina DOUBKOVÁ, Martina PLACKOVA, Veronika MULLER, Michael STUDNICKA, Monika ZURKOVA, Ladislav LACINA, Katarzyna LEWANDOWSKA, Vladimir BARTOS, Petra OVESNÁ, Ondřej MÁJEK and Martina KOZIAR VASAKOVA. The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry. \textit{ARCHIVOS DE BRONCONEUMOLOGIA}. BARCELONA: ELSEVIER ESPANA SLU, 2024, vol.~60, No~2, p.~80-87. ISSN~0300-2896. Available from: https://dx.doi.org/10.1016/j.arbres.2023.12.002.

Detailed Information on Publication Record